Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
Canada permits consideration of off-label clesrovimab for high-risk children during a second season, even though the product is not authorized for that indication.
There's more to see -- the rest of this topic is available only to subscribers.